Pharmacogenomics

Omicron Variant Spreads Throughout South Carolina

Retrieved on: 
Monday, December 20, 2021
COVID-19 testing, Hospital, DNA sequencing, National, CEO, The Founder Institute, Wellness, COVID-19, CLIA, Clemson University, Partnership, Diabetes, Mask, Industry, Population, Multimedia, NIH, COLA, LIS, Omicron, Founder, Pharmacogenomics, NGS, Animal, Pharmaceutical industry, Online shopping, Toxicology, Upstate, Shriners

The laboratory has been surveilling for Omicron and other novel variants through Next Generation Sequencing (NGS) in partnership with the Clemson University Bioengineering Department.

Key Points: 
  • The laboratory has been surveilling for Omicron and other novel variants through Next Generation Sequencing (NGS) in partnership with the Clemson University Bioengineering Department.
  • NGS is the process of decoding the genetic make-up of the virus to track how it is mutating and spreading throughout the population.
  • "Through partnerships like ours with Clemson University, we are happy to increase the amount of data for South Carolina and the entire nation which is vital for vaccine efficacy and our understanding of the virus."
  • Premier Medical Laboratory Services (PMLS), based inGreenville, South Carolina, is an advanced molecular diagnostics lab fully certified by top laboratory accrediting organizations, including CLIA and COLA.

BC Platforms Delivers on Global Real-World Data and Platform Access

Retrieved on: 
Friday, December 17, 2021
NGS, Clinical trial, Pharma, Duchenne muscular dystrophy, BCP, Clinical trials unit, Foundation, Risk, THL, R, Pharmacogenomics, Computer, Disease, Finnish Institute for Health and Welfare, RWD, LinkedIn, MIT, Genomics, Pandemic, University, Johnson & Johnson, Finnish Institute, Informatics, Partnership, Roche, Algorithm, List of life sciences, Lung cancer, COVID-19, CCPM, CEO, Research, Artificial intelligence, Health care, Coronavirus, Medicine, SNV, Precision medicine, Method, EPIC, Company, Industry, BC, Patient, Mortality, Knowledge, Duchenne, Bumrungrad International Hospital, Technology, Pharmaceutical industry

During 2021, BCP has successfully delivered significantly expanded global real-world data (RWD) and platform access in order to support precision medicine-led healthcare research and development (R&D).

Key Points: 
  • During 2021, BCP has successfully delivered significantly expanded global real-world data (RWD) and platform access in order to support precision medicine-led healthcare research and development (R&D).
  • The global footprint of the BC Platforms Data network has grown rapidly to now include RWD equivalent to approximately 25 million patient lives, including longitudinal clinical data in addition to 500k patients' genetic data, across 14 countries in Europe, North and South America, Asia and Africa.
  • BC Platforms is a global leader in providing a powerful data and technology platform for personalized medicine, accelerating the translation of insights into clinical practice.
  • Additionally, BC Platforms has developed a Global Data Partner Network BCRQUEST.com, which allows us to access more than 25 million patients across Europe, Americas, Africa, and Asiawith rich data for pharmaceutical and medical research and development.

BC Platforms Delivers on Global Real-World Data and Platform Access

Retrieved on: 
Friday, December 17, 2021
NGS, Clinical trial, Pharma, Duchenne muscular dystrophy, BCP, Clinical trials unit, Foundation, Risk, THL, R, Pharmacogenomics, Computer, Disease, Finnish Institute for Health and Welfare, RWD, LinkedIn, MIT, Genomics, Pandemic, University, Johnson & Johnson, Finnish Institute, Informatics, Partnership, Roche, Algorithm, List of life sciences, Lung cancer, COVID-19, CCPM, CEO, Research, Artificial intelligence, Health care, Coronavirus, Medicine, SNV, Precision medicine, Method, EPIC, Company, Industry, BC, Patient, Mortality, Knowledge, Duchenne, Bumrungrad International Hospital, Technology, Fine chemical, Pharmaceutical industry

ZURICH, Dec. 17, 2021 /PRNewswire/ -- BC Platforms (BCP), a global leader in healthcare data management and analytics, today announced a new clinical collaboration with the Colorado Center for Personalized Medicine (CCPM) and reported on its outstanding 2021 performance. Its new data partnership with the Colorado Center for Personalized Medicine (CCPM) will support the clinical translation of its basic research, including the potential to ensure improved and more personalized drug compatibility for patients. During 2021, BCP has successfully delivered significantly expanded global real-world data (RWD) and platform access in order to support precision medicine-led healthcare research and development (R&D). Leveraging its Data Network and the flagship BC|INSIGHT platform, which curates and analyses data in a secure format to advance personalized healthcare research, BCP has conducted impactful and transformational initiatives in key areas such as lung cancer, COVID-19, Duchenne muscular dystrophy and several others.

Key Points: 
  • During 2021, BCP has successfully delivered significantly expanded global real-world data (RWD) and platform access in order to support precision medicine-led healthcare research and development (R&D).
  • The global footprint of the BC Platforms Data network has grown rapidly to now include RWD equivalent to approximately 25 million patient lives, including longitudinal clinical data in addition to 500k patients' genetic data, across 14 countries in Europe, North and South America, Asia and Africa.
  • BC Platforms is a global leader in providing a powerful data and technology platform for personalized medicine, accelerating the translation of insights into clinical practice.
  • Additionally, BC Platforms has developed a Global Data Partner Network BCRQUEST.com, which allows us to access more than 25 million patients across Europe, Americas, Africa, and Asiawith rich data for pharmaceutical and medical research and development.

GenXys Inks Deal with Precision Genetics for Personalized Medicine

Retrieved on: 
Wednesday, December 15, 2021
Pharmacogenomics, Pharmacy, Solution, Insurance, Population, Health, Genetics, Business development, CEO, Safety, Patient, Population health, Mental health, Software, Patient safety, Disulfiram-like drug, Disability, Galveston National Laboratory, Precision medicine, Medical device, Pharmaceutical industry, BC, Science

VANCOUVER, BC, Dec. 15, 2021 /PRNewswire/ -- GenXys Healthcare Systems Inc. (GenXys) is adding a new value dimension to Precision Genetics and the personalized health marketplace. Precision prescribing has become a leading method to bring pharmacogenetics (PGx) closer to the standard of care for certain conditions that often carry a high cost and a lower rate of medication effectiveness. Precision Genetics will use GenXys's award-winning suite of software solutions, IdentifyPGx™, TreatGx™, and ReviewGx™ to embed pharmacogenetics and offer an improved and transformative approach to precision prescribing.

Key Points: 
  • Tailored treatments using a multifactorial, comprehensive prescribing solution will prevent adverse drug reactions and improve outcomes
    VANCOUVER, BC, Dec. 15, 2021 /PRNewswire/ -- GenXys Healthcare Systems Inc. (GenXys) is adding a new value dimension to Precision Genetics and the personalized health marketplace.
  • Precision Genetics will use GenXys's award-winning suite of software solutions, IdentifyPGx, TreatGx, and ReviewGx to embed pharmacogenetics and offer an improved and transformative approach to precision prescribing.
  • IdentifyPGx has already enabled Precision Genetics to effectively identify which patient populations will benefit most from PGx testing.
  • GenXys provides the world's most comprehensive precision prescribing solutions with embedded pharmacogenetics to solve one of healthcare's biggest challenges; trial-and-error prescribing.

imaware Welcomes New President Paul Owen

Retrieved on: 
Wednesday, December 1, 2021
Patient, Mayo Clinic, API, Judgement, CEO, Degenerative disease, Technology, Genetic testing, Industry, Health, Precision medicine, Pharmacogenomics, COO, Solution, Genetics, Digital, Men's Health, Multimedia, Growth, Management, Medical device

Digital health solutions company imaware, today announced Paul Owen will join the company as its new President.

Key Points: 
  • Digital health solutions company imaware, today announced Paul Owen will join the company as its new President.
  • As President, Owen will drive imaware's vision and strategy for continued growth as the company has seen an increased demand for home-based tests and the need for personalized digital health solutions.
  • Owen is a demonstrated leader and innovator, drawing from his vast experience in the biotech, genetics, pharmacogenetics and digital industries in key executive leadership roles.
  • "Paul brings a wealth of expertise which will be incredibly valuable as we continue to execute on imaware's strategic path.

Global Therapeutic Drug Monitoring Markets, Technology, & Competitive Landscape Research Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, November 30, 2021
Health, Pharmaceutical, Therapeutic drug monitoring, TDM, Company, Pharmacogenomics, Pharmacokinetics, Health, Blood, Sexual abuse, Method, DOA, Medical device, Pharmaceutical industry

The "Therapeutic Drug Monitoring - Technologies, Markets & Companies" report from Jain PharmaBiotech has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Therapeutic Drug Monitoring - Technologies, Markets & Companies" report from Jain PharmaBiotech has been added to ResearchAndMarkets.com's offering.
  • This report deals with therapeutic drug monitoring, a multi-disciplinary clinical specialty, aimed at improving patient care by monitoring drug levels in the blood to individually adjust the dose of drugs for improving outcomes.
  • TDM is viewed as a component of personalized medicine that interacts with several other disciplines including pharmacokinetics and pharmacogenetics.
  • The report contains profiles of 35 companies involved in developing tests and equipment for drug monitoring along with their collaborations.

AmMax Bio Hosting Key Opinion Leader Webinar on AMB-05X for the Treatment of Tenosynovial Giant Cell Tumor (TGCT)

Retrieved on: 
Tuesday, November 30, 2021
Giant, Patient, Organization, Leiden University Medical Center, Tenosynovial giant cell tumor, Idiopathic pulmonary fibrosis, Cell, Oncology, CSF1, KOL, Sarcoma, Pharmacogenomics, Doctor of Philosophy, National Wilms Tumor Study Group, Advisory Committee on Immunization Practices, Bone tumor, Pain, Quality of life, Research, Risk, Disability, IPF, Adult, Incidence, Health, Infection, Administration, GLOBE, Q&A, Macrophage, GIST, EPOS, Stromal cell, EORTC, Principal investigator, CSF1R, LUMC, Department, Adolescence, Vaccine, Medicine, Medical imaging

REDWOOD CITY, Calif., Nov. 30, 2021 (GLOBE NEWSWIRE) -- AmMax Bio, Inc. (“AmMax”), a private clinical-stage biotech company developing novel treatments with AMB-05X, its proprietary anti-CSF1R monoclonal antibody platform, today announced that it will host a key opinion leader (KOL) webinar on AMB-05X and its potential as a new standard of care in the treatment of tenosynovial giant cell tumor (TGCT).

Key Points: 
  • Professor Gelderblom has served as a Principal Investigator on multiple clinical trials for tenosynovial giant cell tumor (TGCT) and is currently a key scientific advisor and Investigator to AmMax Bios TGCT clinical development program.
  • Prof. van de Sande has participated in numerous tenosynovial giant cell tumor (TGCT) trials and is a key scientific advisor and Investigator to AmMax Bios TGCT clinical development program.
  • AmMax is enrolling patients in a Phase 2 clinical program for tenosynovial giant cell tumor (TGCT).
  • Based on robust preclinical proof-of-concept results, AmMax is also planning to initiate a Phase 2 clinical study in idiopathic pulmonary fibrosis (IPF).

Global Personalized Medicine Market Research Report 2021 with Focus on Scientific & Commercial Aspects, Competitive Landscape & Key Markets - ResearchAndMarkets.com

Retrieved on: 
Tuesday, November 30, 2021
Health, Pharmaceutical, Drug resistance, Table, Genomics, Safety, Cell, Basic, Genetic testing, Publication, Cancer, Pharmacogenomics, Gene expression, Metabolism, Biomarker, Metabolomics, SNP, Family, Bibliography, Science, Schizophrenia, Biotechnology, Diagnosis, FDA, Drug discovery, Medicine, Vaccine, Lists of diseases, Biochip, Disease, Enzyme, Gene, HIV/AIDS, Dentistry, Medical imaging, Pharmaceutical industry

The "Personalized Medicine - Scientific & Commercial Aspects" report from Jain PharmaBiotech has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Personalized Medicine - Scientific & Commercial Aspects" report from Jain PharmaBiotech has been added to ResearchAndMarkets.com's offering.
  • This report describes the latest concepts of the development of personalized medicine based on pharmacogenomics, pharmacogenetics, pharmacoproteomics, and metabolomics.
  • There is an emphasis on early detection and prevention of disease in modern medicine.
  • The concept of personalized medicine described in this report remains the best way to integrate new technologies such as nanobiotechnology for improving healthcare.

Global Biomarkers Markets, Technology & Competitive Landscape Report 2020-2021 & 2030: Focus on Proteomics, Metabolomics, Molecular Diagnostics, Drug Discovery, Clinical Trials, and Bioinformatics - ResearchAndMarkets.com

Retrieved on: 
Monday, November 29, 2021
Biotechnology, General Health, Health, Diagnosis, Degenerative disease, Cancer, Genomics, Research, Company, Pharmacogenomics, Central nervous system, Biomarker, Industry, Classification, Therapy, Drug discovery, Proteomics, Metabolomics, Medical imaging, Pharmaceutical industry

This report describes different types of biomarkers and their discovery using various "-omics" technologies such as proteomics and metabolomics.

Key Points: 
  • This report describes different types of biomarkers and their discovery using various "-omics" technologies such as proteomics and metabolomics.
  • Molecular diagnostics technologies are used for the discovery of biomarkers and new tests are also based on biomarkers.
  • The role of biomarkers in various therapeutic areas particularly cancer, cardiovascular diseases and disorders of the central nervous system, is described.
  • Biomarker markets are estimated from 2020 to 2030 according to share of markets for various technologies and applications: proteomics, metabolomics, molecular diagnostics, drug discovery, clinical trials, and bioinformatics.

Agena Bioscience® and Manchester University Announce Partnership to Provide Educational Resources to the Pharmacogenomics Industry

Retrieved on: 
Monday, November 29, 2021
Pharming, Genetic testing, Industry, Partnership, Awareness, Health, Master of Science, Precision medicine, Student, Pharmacogenomics, Graduate certificate, Pharmacokinetics, SAN, Education, Program, Physician, Research, Genetics, Knowledge, Mesa, Infection, Multimedia, University of Manchester, EUA, MU, Growth, Quality of life, Pharmaceutical industry, Medicine

SAN DIEGO, Nov. 29, 2021 /PRNewswire/ --Agena Bioscience (part of Mesa Labs' Clinical Genomics Division), a global provider of genetic testing solutions, today announced a partnership with Manchester University (MU) to expand awareness and access to PGx educational resources.

Key Points: 
  • SAN DIEGO, Nov. 29, 2021 /PRNewswire/ --Agena Bioscience (part of Mesa Labs' Clinical Genomics Division), a global provider of genetic testing solutions, today announced a partnership with Manchester University (MU) to expand awareness and access to PGx educational resources.
  • This partnership will enable Agena Bioscience to promote and offer its customers the established MU PGx programs, including the Graduate Certificate in PGx or Master of Science in PGx degree.
  • "We are thrilled to partner with Agena Bioscience, an industry leader in the PGx space, to offer our programs to a broader audience."
  • With this partnership, Agena Bioscience and Manchester University strive to provide additional educational resources to support continued growth in this exciting field.